llrx-royce.blogspot.com
Houston-based ITS said it also has expandexd its ongoing collaborative relationship with through completion of additional production serviceds forthat company. Aggregate proceeds to ITS from these contracts totak morethan $1 million. Under the termsd of these new agreements, ITS will produce high-grade biologicw for use in clinical trials for severao types ofcancer treatment. “The signing and executiojn of these new manufacturint agreements provide tremendous validation for ITS and the manufacturing serviceas that we offer to leadinb companies and academic institutions in the area of drug developmentgand research,” said David Enloe, ITS president and chiev executive officer.
, an Austin-baser biopharmaceutical company that is the parentof ITS, filed for Chapteer 11 bankruptcy protection in December. As part of its restructuring effort, Introgen said it hoped to sell its therapeutic producgt portfolio and reorganize around its contract manufacturingh businessin Houston.
No comments:
Post a Comment